miRNA analysis study using a peptide vaccine for pancreatic cancer after surgery clinical trial subjects serum

miRNA analysis study using a peptide vaccine for pancreatic cancer after surgery clinical trial subjects serum - miRNA analysis study using a peptide vaccine for pancreatic cancer after surgery clinical trial subjects serum

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000013053

Enrollment

Registered

2014-02-03

Start date

2012-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with the consent of the peptide vaccine clinical research pancreatic cancer after surgery and the postoperative GEM clinical research at the Wakayama Medical University Hospital

Exclusion criteria

Exclusion criteria: Not obtained the consent

Design outcomes

Primary

Measure	Time frame
The patient serum are measured comprehensively by the miRNA array analysis. This study comprehensively analyzes the expression in the specimens for all of about 1700 human miRNA (as of April 2012) which are registered in the miRBase which is a database of miRNA. Measurement method performs by next-generation sequencing in the research institutes, and we perform the extraction of RNA from the specimen, and the measurement of miRNA using the 3D-Gene &reg; miRNA oligo chip24.	—

Measure

Time frame

The patient serum are measured comprehensively by the miRNA array analysis. This study comprehensively analyzes the expression in the specimens for all of about 1700 human miRNA (as of April 2012) which are registered in the miRBase which is a database of miRNA. Measurement method performs by next-generation sequencing in the research institutes, and we perform the extraction of RNA from the specimen, and the measurement of miRNA using the 3D-Gene &reg; miRNA oligo chip24.

—

Countries

Japan

Contacts

Public ContactKen Ishii

National Institutes of Biomedical Innovation,Health and Nutrition Laboratory of Adjuvant Innovation

kenishii@biken.osaka-u.ac.jp072-641-8043

Outcome results